MENAC: The Multimodal Exercise/Nutrition/Anti-inflammatory treatment for Cachexia trial
MENAC is a large-scale open randomised phase III, multimodal intervention trial.
To establish whether a multimodal intervention is effective in treating cachexia. This will be assessed after 2 cycles of chemotherapy (study endpoint -between 6 -9 weeks) by measuring weight. Importantly, benefits of trial will set a foundation for future nutritional and physical intervention for patients undergoing chemotherapy, an area that today is regularly neglected.
To examine the effect of a multimodal intervention for cancer cachexia on muscle mass (CT at L3) and physical activity (ActivPAL).
- Diagnosis of lung cancer, pancreatic cancer or cholangiocarcinoma
- Due to commence anti-cancer therapy
Patients and recruitment
A total of 240 patients will be recruited from out-patient oncology clinics at multiple sites in Europe, Canada and Australia.
The trial is open for inclusion at 12 centers in Norway, UK, Canada, Germany and Switzerland. By August 2018, 91 patients are enrolled in the trial.
PIs: Professor Stein Kaasa, NTNU/Oslo University Hospital and Professor Marie Fallon, University of Edinburgh.
For more information, or if your centre is interested in recruiting patients, please contact trial coordinator Inger Storaker (firstname.lastname@example.org).
MENAC related publications
Balstad TR et al: Dietary treatment of weight loss in patients with advanced cancer and cachexia: a systematic literature review. Crit Rev Oncol Hematol. 2014
Balstad TR et al: Multimodal nutrition/anabolic therapy for wasting conditions. Curr Opin Clin Nutr Metab Care. 2014
Solheim TS et al: Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol 2013
Blum D & Strasser F: Cachexia assessment tools. Curr Opin Support Palliat Care 2011
Blum D et al: Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit Rev Oncol Hematol. 2011